. 2018 Nov 22;10:6217–6226. doi: 10.2147/CMAR.S176918

Table 2.

Stepwise regression of C_{SN-38 1.5h}, C_{SN-38 49h}, and DPD activity for *1/*28-*1/*1 and *1/*1-*1/*6 genotypes

	Associated clinical parameters	95% CI		t	P-value	Mean of adjusted predicted value	Standard error of predicted value
	Associated clinical parameters	Lower	Upper	t	P-value	Mean of adjusted predicted value	Standard error of predicted value
C_{SN-38 1.5h} (ng/mL)	Constant	20.21	29.36			62.51	10.69
C_{SN-38 1.5h} (ng/mL)	PFS	5.77	7.30	16.81	<0.001	62.51	10.69
C_{SN-38 49h} (ng/mL)	Constant	6.34	7.66	20.92		10.84	3.50
	Bone marrow hypocellularity	2.14	3.37	8.82	<0.001
	Increased alanine aminotransferase	1.19	2.73	5.02	<0.001
	Diarrhea	1.37	3.24	4.84	<0.001
DPD activity	Constant	4.89	5.75	24.20		4.66	0.53
	Bone marrow hypocellularity	−1.23	−0.20	−2.75	0.007
	Increased alanine aminotransferase	−0.81	−0.17	−3.03	0.003

Abbreviations: CPT-11, irinotecan; C_{SN-38 1.5h}, plasma SN-38 level 1.5 hours after CPT-11 administration; C_{SN-38 49h}, plasma SN-38 level 49 hours after CPT-11 administration; DPD, dihydropyrimidine dehydrogenase; PFS, progression-free survival.